


# A BLASTP Parameters:

Expect Threshold: 10  
Word size: 3  
Max matches in a query range: 0  
Matrix: BLOSUM62  
Gap Costs: existence 10, extension 1\*  
Compositional Adjustments: Conditional  
compositional score matrix adjustment

\*Default values are: existence 11, extension 1.

# B



# C

**Identities = 80/345 (23%), Positives = 118/345 (34%), Gaps = 92/345 (26%)**

```
Msh 3 SKVTILDGGMGRELLRNGAPFRQPEWSALSLIEAPEFVKMAHDAFVAAGA EVITTSYAL 62
      ++ LDG M EL G + WSA L+E PE+++ H + AGA+ T SY
MmuM 14 QDILLLDGAMATELEARGCNLADSLWSAKVLVENPELIREVHLDYYRAGAQC AITASYQA 73

Msh 63 VPFHIGDQALPH---MGLLSPIYPAARSCRRA-----EGTTVCTG----- 99
      P + L L+ AR R A GT + G
MmuM 74 TPAGFAARGLDEAQS KALIGKSVELARKAREAYLAENPQAGTLLVAGSVGPY GAYLADGS 133


Msh 100 -----CRLSA-----PRLRL---PARFVRCRQGACHSRYP RQSPKLLTSISGSPRP 143
      C + A PR+ L A ++ C S + L ++ PR
MmuM 134 EYRGDYHCSVEAFQAFHRPRVEALLDAGADLLACETLPNFS---EIEALAE LLTAYPRA 189

Msh 144 RAPSRRSKQIRNDIGLRLRGPVGFYARRTTKSVADVICLVSVPTLVSG--EAVAQR RS 201
      RA F + R ++ ++D L V L++G + V
MmuM 190 RA-----WFSFTLRDSEHLS DGTPLRDVVALLAGYPQVV----- 223


Msh 202 QSSAACAGALLFNCSQAEIMEAGVKSANQALKADNLDIPIGVYANAFV PKPETEESLAAN 261
      AL NC E +A Q L + +P+ VY N+ ++ +
MmuM 224 -----ALGINCIALE-----NTTAA LQHHLGLTV-LPLVVYPNSGEHYDAVSKTWHHH 270

Msh 262 DGLSGLRDDLNPSGYLQFAQRWVSAGATIIGGCCGIGPEHIAELK 306
      D P +W +AGA +IGGCC P IA LK
MmuM 271 GEHCAQLADYLP-----QWQAAGARLIGGCCRTTPADIAALK 307
```


**Supplementary Figure S1** End-to-end sequence similarity between Msh and the MmuM protein of *E. coli*. (A) BLAST parameters. (B) Msh and MmuM amino acid sequence alignment. (C) Scatter plot of the amino acid comparison between Msh and MmuM.




**Supplementary Figure S2.** Detection of octopine and sulfonopine by ESI-MS/MS in the Ocs enzymatic reaction. The enzymatic reactions contain 150 mM PIPES pH6.6 buffer, 10 mM of pyruvate, 10 mM of NADPH and 10 mM of amino acid (arginine or SMM) and 0.08  $\mu$ M Ocs. (A) Control enzymatic reaction- no amino acid. (B) Reaction with arginine. (C) Reaction with SMM. X-axis molecular weight and y-axis peak intensity. Peaks 93, 115 and 207 are compounds from the enzymatic reaction.





**Supplementary Figure S3.** Authentication of sulfonopine production: (A) chemically synthesized, (B) enzymatically synthesized, (C) *Arabidopsis* tissue, (D) tobacco seedling tissue and (E) in tobacco seedling exudates. The authentication of sulfonopine was done by fragmenting it and comparing the fragments with the authentic compound chemically synthesized. Sulfonopine has two fingerprint fragments, which have a molecular weight of 174 and 128.



Supplementary Figure S4. <sup>1</sup>H NMR spectrum of Sulfonopine in D<sub>2</sub>O. x-axis parts per Million. y-axis abundance.



**Supplementary Figure S5.** Induction of *occ* operon by octopine-type opines and amino acids.  $\beta$ -glucuronidase specific activity of *ooxA-uidA* strain KYC16 cultured in the presence of cultured in the presence of (A) exudates or (B) tissue homogenates from infected tobacco seedlings or in the presence of amino acids (C). Mean  $\pm$  SD of n=3. \*P<0.001, *t* test relative to none sample.

**A****B**

**Supplementary Figure S6.** Induction of *occ* operon by octopine-type opines. (A)  $\beta$ -galactosidase activity of *A. tumefaciens* KYC1203 (pKYC148) ( $\Delta occR$ ) cultured in the presence of different opines. pKYC148 contains an *occQ-lacZ* translational fusion. (B)  $\beta$ -glucuronidase specific activity of *ooxA-uidA* strain KYC16 cultured in the presence of SMM and Sulfonopine. Mean  $\pm$  SD of n=3. \*P<0.001, *t* test relative to none sample.

Table S1. Bacterial Strains and plasmid used in this study

Strains or plasmids	Relevant features	References
BL21/DE3	<i>E. coli</i> P <sub>lac</sub> -gene 1 of bacteriophage T7	(Studier et al., 1990)
S17-1/λpir	RK2, <i>tra</i> regulon, <i>pir</i> , host for <i>pir</i> -dependent plasmid	(Simon et al., 1983)
R10	<i>A. tumefaciens</i> R10	(S. K. Farrand)
KYC55	<i>A. tumefaciens</i> R10, Ti plasmid less	(Cho et al. 1997)
KYC16	R10 ( <i>ooxA</i> ::Tn5 <i>gusA7</i> ), Km <sup>R</sup>	(Cho et al. 1996)
ALFM20	R10::pAFM110, <i>ocs</i> -lacZ, Km <sup>R</sup>	This study
ALFM21	R10::pAFM111, <i>virD4</i> -lacZ, Km <sup>R</sup>	This study
<b>Plasmids</b>		
pVIK107	<i>lacZY</i> for translational fusions, Km <sup>R</sup>	(Kalogeraki and Winans, 1996)
pMCSG19	P <sub>T7</sub> -MBP-TVMV-his <sub>6</sub> -TEV, Amp <sup>R</sup>	(Donnelly et al. 2005)
PT7-groE	P <sub>T7</sub> - <i>groESL</i> , ColE1; Cm <sup>R</sup>	(Yasukawa et al., 1995)
pRK1037	P <sub>L</sub> -tetO-TVMV protease, Km <sup>R</sup>	(Donnelly et al. 2005)
pAFM04	<i>ocs</i> cloned into pMCSG19, Amp <sup>R</sup>	This study
pAFM11	<i>msh</i> cloned into pMCSG19, Amp <sup>R</sup>	This study
pAFM110	pVIK107, <i>ocs</i> internal fragment, in-frame translational fusion	This study
pAFM111	pVIK107, <i>virD4</i> internal fragment, in-frame translational fusion	This study

Table S2. Oligonucleotides used in this study

<b>Oligonucleotide Name</b>	<b>DNA Sequence</b>
ALFM21	5'-CGCGGATCCATGTCATCGAAAGTC-3'
ALFM27	5'-ATA GTTTAGCGGCCGCTC AGGCTGCGG C-3'
ALFM28	5'-TACTTCCAATCCAATGCAATGGCTAAAGTGGCA-3'
ALFM29	5'-TTATCCACTAATTCAAACCTCCATTGAG-3'
ALFM218	5'-GGGGTACCTCGGTCCTCGTAGCATTGCCC-3'
ALFM219	5'-CGCGGATCCTCTTGGAGTTTCGATATCAGC-3'
ALFM220	5'-GGGGTACCATTGGCGAAATGCAGCATGCT-3'
ALFM221	5'-CGCGGATCCTAGGCTTTCCTCCGCGAGTTG-3'